1 / 11

APPROACH TO LYMPHOID MALIGNANCIES

APPROACH TO LYMPHOID MALIGNANCIES. Patient Evaluation of ALL. Careful history and PE CBC Chemistry studies Bone marrow biopsy Lumbar puncture. Prognostic Factors. genetic characteristics of the tumor patient’s age WBC count function of major organs. Patient Evaluation of CLL.

scott
Download Presentation

APPROACH TO LYMPHOID MALIGNANCIES

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. APPROACH TO LYMPHOID MALIGNANCIES

  2. Patient Evaluation of ALL • Careful history and PE • CBC • Chemistry studies • Bone marrow biopsy • Lumbar puncture

  3. Prognostic Factors • genetic characteristics of the tumor • patient’s age • WBC count • function of major organs

  4. Patient Evaluation of CLL • Careful history and PE • CBC • Chemistry studies • Serumprotein electrophoresis • Bone marrow biopsy • Imaging studies of thechest and abdomen for pathologic lymphadenopathy

  5. Major Prognostic Groups Good prognosis (+) blood and bone marrowinvolvement Intermediate prognosis (+) lymphadenopathy (+) organomegaly Poor prognosis (+) bone marrow failure • Hgb <10g/dL • Platelet count <100,000/iL

  6. Immunologic abnormalities in CLL • Autoimmune hemolytic anemia • Autoimmunethrombocytopenia • Hypogammaglobulinemia

  7. Patient evaluation of Hodgkin’s Disease • Careful history and physical examination • CBC • Erythrocyte sedimentation rate (ESR) • Chemistry studies of major organ function • CT scan of chest, abdomen and pelvis • Bone marrow biopsy

  8. Ann Arbor Staging for Hodgkin’s Disease

  9. Patient evaluation of Non – Hodgkin’s Disease • Careful history and physical examination • CBC • Erythrocyte sedimentation rate (ESR) • Chemistry studies of major organ function • CT scan of chest, abdomen and pelvis • PET and gallium scan for more aggressive subtypes (e.g.diffuse large B cell lympoma) • Bone marrow biopsy ESR • Serum lactate dehydrogenase (LDH) • β2 – microglobulin • Serum protein electrophoresis

  10. International Prognostic Index for NHL Five clinical risk factors: • Age > 60 years • Serum lactase dehydrogenase levels elevated • Performance status >2 (ECOG) or <70 (Karnofsky) • Ann Arbor stage III or IV • >1 site of extranodal involvement

  11. International Prognostic Index for NHL Patients are assigned a number for each risk factor they have Patients are grouped differently based upon the type of lymphoma For diffuse large B cell lymphoma: 0,1 factor = low risk 35% of cases; 5 – yr survival, 73% 2 factors = low – intermediate risk 27% of cases; 5 – yr survival, 51% 3 factors = high – intermediate risk 22% of cases; 5 – yr survival, 43% 4,5 factors = high risk 16% of cases; 5 – yr survival, 26% For diffuse large B cell lymphoma treated with R – CHOP: 0 factor = very good 10% of cases; 5 – yr survival, 94% 1,2 factors = good 45% of cases; 5 – yr survival, 79% 3,4,5 factors = poor 45% of cases; 5 – yr survival, 55%

More Related